FDA officials say they’ll place renewed emphasis on advisory meetings for contested product applications.
Under new leadership, FDA officials have said they’ll place renewed emphasis on advisory meetings for contested product applications.
Two new announcements suggest they’re making good …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection
FDA advisors back approval of mRNA flu shot
New ACIP charter broadens criteria for members, calls for review of alternatives to vaccines
On second try, Acadia drug gets nod from European regulators
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and…
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more…
Replimune will resubmit advanced melanoma drug RP1 to the FDA after two rejections, following the ouster of Commissioner Marty…
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance…
Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
Changes made this week to the rules controlling how the CDC’s influential vaccine advisory panel operates could open the door for…
